<DOC>
	<DOCNO>NCT00270491</DOCNO>
	<brief_summary>Tolerance efficacy administration capecitabine 5 7 day associate weekly paclitaxel compare recommend treatment plan weekly paclitaxel - capecitabine , patient metastatic breast cancer .</brief_summary>
	<brief_title>Capecitabine Associated With Weekly Paclitaxel Metastatic Breast Cancer .</brief_title>
	<detailed_description>The purpose study know optimize term tolerance even efficacy plan administration weekly paclitaxel associate capecitabine .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Femal patient age &gt; 18 year Histologically proven breast adenocarcinoma HER2 negative receptor previously receive first second line chemotherapy metastatic disease previously treat anthracycline and/or docetaxel adjuvant and/or first second line therapy presence one several evaluable metastatic lesion ( ) presence least one target lesion previously irradiate previously treat hormonotherapy adjuvant metastatic line ( treatment cease upon patient registration study ) ECOG Performance status &lt; 2 adequate biological value patient clearly give consent signing informed consent form prior participation patient previously treat paclitaxel capecitabine metastatic breast cancer patient local metastatic disease ( exception axillary lymph node ) active symptomatic brain metastasis patient history significant cardiovascular impairment ( congestive heart failure &gt; NYHA grade II , unstable angina myocardial infraction within past six month serious cardiac arrhythmia ) peripheric neuropathy grade â‰¥ 2 history another malignancy within past 5 year could confound diagnosis stag breast cancer ( exception situ cacinoma cervix adequately treat basel cell carcinoma skin ) patient medical psychiatric condition , opinion Principal Investigator , would preclude participate study patient know allergy one several study compound patient may regularly available due geographical , social family reason history renal , hepatic metabolic pathology could preclude metabolism elimination study product deficiency upper intestinal tract , malabsorption syndrome patient pregnant , breastfeed use inadequate contraception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>